Eurofins Scient (OTCMKTS:ERFSF) Hits New 52-Week High – Still a Buy?

Eurofins Scient (OTCMKTS:ERFSF) reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $86.20 and last traded at $83.00, with a volume of 2541 shares changing hands. The stock had previously closed at $85.7720.

Analyst Ratings Changes

ERFSF has been the topic of a number of recent research reports. Citigroup restated a “neutral” rating on shares of Eurofins Scient in a report on Wednesday, October 22nd. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Eurofins Scient in a report on Wednesday, October 29th. Finally, BNP Paribas Exane upgraded shares of Eurofins Scient to an “outperform” rating in a report on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy”.

Eurofins Scient Stock Performance

The company has a quick ratio of 1.19, a current ratio of 1.26 and a debt-to-equity ratio of 0.77. The business has a fifty day moving average price of $74.62 and a two-hundred day moving average price of $74.28.

About Eurofins Scient

Eurofins Scientific is a global provider of bioanalytical testing and laboratory services, offering a wide array of testing solutions to pharmaceutical, food, environmental, agriscience and consumer products industries. Its core services include pharmaceutical quality control, environmental testing for water and air quality, food safety analysis, agrochemical trials and clinical diagnostic support. The company operates specialized laboratories equipped with advanced analytical technologies such as chromatography, mass spectrometry and molecular biology to ensure compliance with regulatory standards and to support research and development efforts across multiple sectors.

Founded in 1987 by Gilles Martin and headquartered in Luxembourg, Eurofins has grown through a combination of organic expansion and strategic acquisitions.